(Q38175868)

30 August 2017

title

PI3-kinase inhibitors in chronic lymphocytic leukemia (English)

1 reference

30 August 2017

0 references

Julie E Chang

1

1 reference

30 August 2017

Brad S Kahl

series ordinal

2

1 reference

30 August 2017

publication date

1 March 2014

1 reference

Current hematologic malignancy reports

30 August 2017

published in

1 reference

30 August 2017

volume

9

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

33-43

1 reference

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Phosphoinositide signalling in cancer: beyond PI3K and PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

The emerging mechanisms of isoform-specific PI3K signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

p110δ, a novel phosphoinositide 3-kinase in leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Signaling by the phosphoinositide 3-kinase family in immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Inhibitors of B-cell receptor signaling for patients with B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0189-7

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24390602

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chronic lymphocytic leukemia with deletion 17p: emerging treatment options

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24390602

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phosphoinositide 3-kinase signalling pathways

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24390602

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11899-013-0189-7

1 reference

Dimensions Publication ID

30 August 2017

1018299395

0 references

1 reference